News
Abiraterone and Enzalutamide Thwart Prostate Cancer Pain
Major Findings: Abiraterone acetate reduced opiate use by 19%, and enzalutamide the risk of pain progression by 44%.
News
EMILIA Confirms T-DM1 Overall Survival Advantage
Major Finding: Median overall survival was 30.9 months for T-DM1 and 25.1 months for capecitabine plus lapatinib (hazard ratio = 0.68, P = .0006)....
News
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
Major Findings: The hazard ratios for disease-free and overall survival comparing 1 year and 2 years of adjuvant trastuzumab in the HERA trial...
News
Dual Kinase Therapy Slows BRAF-Mutated Metastatic Melanoma
Major Findings: Progression-free survival was 9.4 months using a combination of dabrafenib 150 mg and trametinib 2 mg as compared with 5.8 months...
News
Early BCR-ABL Predicts Survival in Nilotinib-Treated CML
Major Finding: In the nilotinib-treated group, 96.9% of those who achieved BCR-ABL transcript levels of 1% or less and 98.8% of those who achieved...
News
CNS Events Not Immediately Fatal in Mantle Cell Lymphomas
Major Finding: Crude prevalences of CNS involvement at diagnosis and overall were 0.9% and 4.1%, respectively, with a median time to an event of...
News
Elderly Lymphoma Patients Might Be Spared Radiotherapy
Major Finding: After multivariate adjustment, 3-year EFS, PFS, and OS were no different in patients who had received radiotherapy for bulky...
News
Evidence Mounts for Crizotinib Efficacy in ALK-Positive Lymphoma
Major Finding: Eight of nine patients responded to crizotinib, and four had durable responses lasting more than 6 months.Data Source: Nine adults...
News
Regorafenib Delays Progression of Refractory Metastatic GIST
Major Finding: Median progression-free survival was 4.8 months with regorafenib vs.
News
Scleroderma Malignancy Risk Linked to Antinuclear Antibodies
Major Finding: More than half (55.5%) of 154 patents who developed cancer within 3 years of their scleroderma diagnosis had autoantibodies...